# Vertex Seals $10 Billion Acquisition of Crinetics Pharmaceuticals

> ma · REPORTED · 2026-07-13

Vertex Pharmaceuticals announced a $10 billion deal to acquire Crinetics, a rare endocrine disease specialist, in one of the largest biotech M&A transactions of mid-2026. The acquisition significantly expands Vertex's rare disease portfolio beyond its established cystic fibrosis franchise.

About Vertex Pharmaceuticals: Vertex Pharmaceuticals is a global biotechnology company that develops and commercializes medicines for serious diseases, most notably cystic fibrosis, and is expanding into other rare disease areas.

- Company: Vertex Pharmaceuticals
- Sector: biotech
- Primary source: https://lifesciencedaily.news/weekly-news-roundup-20-july-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.